{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-21-041062","form_type":"8-K","ticker":"CLNN","cik":"0001822791","company_name":"Clene Inc.","filed_at":"2021-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.878903+00:00","generated_at":"2026-06-29T19:17:47.834480+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Clene appoints Dr. Vallerie McLaughlin as independent director, effective August 5, 2021","bullets":["Appointed Vallerie V. McLaughlin, M.D. as Class III director and member of Nominating and Corporate Governance Committee.","Received option award for 45,000 shares at $9.37 exercise price, vesting in 36 monthly installments.","Also received immediate options valued at $11,000 (Board $10,000 + committee $1,000) at $9.37 exercise price.","Dr. McLaughlin is professor at University of Michigan, expert in pulmonary hypertension rare disease trials.","She becomes the seventh independent director on the seven-member board."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-21-041062","json":"https://secwatch.observer/filing/0001213900-21-041062.json","markdown":"https://secwatch.observer/filing/0001213900-21-041062.md","text":"https://secwatch.observer/filing/0001213900-21-041062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822791/000121390021041062/0001213900-21-041062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822791/000121390021041062/ea145457-8k_cleneinc.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T19:17:47.834480+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f4942c5b53","claim":"Vallerie V. McLaughlin, M.D. was appointed as Director at Clene Inc..","evidence_excerpt":"On August 5, 2021, the Board of Directors (the “Board”) of Clene Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Vallerie V. McLaughlin, M.D. as a member of the Board, effective August 5, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822791/000121390021041062/0001213900-21-041062-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}